Stock Exchange:
NEW YORK
Sector:
Biotechnology
Sub-sector:
Development
Turnover last year:
1.886 M$ 2023
Profits last year:
282,8 M$ 2023
Activity: biotechnology.
Medpace (Clinical Contract Research or CRO) provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries.
https://www.medpace.com/